Integer (NYSE:ITGR) Reaches New 52-Week High at $119.51

Integer Holdings Co. (NYSE:ITGR - Get Free Report) reached a new 52-week high on Monday . The stock traded as high as $119.51 and last traded at $119.48, with a volume of 33983 shares trading hands. The stock had previously closed at $115.77.

Wall Street Analysts Forecast Growth

ITGR has been the subject of several analyst reports. KeyCorp boosted their target price on Integer from $123.00 to $139.00 and gave the stock an "overweight" rating in a report on Tuesday, April 9th. CL King initiated coverage on shares of Integer in a research note on Thursday, March 14th. They set a "buy" rating and a $137.00 price target on the stock. Benchmark increased their price objective on shares of Integer from $105.00 to $130.00 and gave the company a "buy" rating in a research note on Thursday, March 28th. Finally, Bank of America raised Integer from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $105.00 to $135.00 in a report on Monday. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Integer currently has an average rating of "Moderate Buy" and an average target price of $120.50.

Integer Stock Performance

The company has a current ratio of 2.80, a quick ratio of 1.71 and a debt-to-equity ratio of 0.64. The company has a market cap of $3.98 billion, a P/E ratio of 44.11, a price-to-earnings-growth ratio of 1.46 and a beta of 1.10. The company has a 50 day moving average price of $110.49 and a 200-day moving average price of $97.38.

Integer (NYSE:ITGR - Get Free Report) last issued its quarterly earnings results on Thursday, February 15th. The medical equipment provider reported $1.39 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.05. The company had revenue of $413.15 million during the quarter, compared to analysts' expectations of $409.04 million. Integer had a return on equity of 10.80% and a net margin of 5.68%. The business's quarterly revenue was up 10.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.11 earnings per share. On average, equities analysts expect that Integer Holdings Co. will post 5.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Raymond James & Associates boosted its position in shares of Integer by 12.6% during the 1st quarter. Raymond James & Associates now owns 40,898 shares of the medical equipment provider's stock valued at $3,295,000 after acquiring an additional 4,578 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Integer by 1.3% during the first quarter. Bank of New York Mellon Corp now owns 406,645 shares of the medical equipment provider's stock valued at $32,763,000 after purchasing an additional 5,256 shares during the period. American Century Companies Inc. grew its holdings in Integer by 20.9% in the 1st quarter. American Century Companies Inc. now owns 5,573 shares of the medical equipment provider's stock worth $449,000 after acquiring an additional 963 shares during the last quarter. US Bancorp DE lifted its holdings in Integer by 11.8% in the 1st quarter. US Bancorp DE now owns 9,970 shares of the medical equipment provider's stock worth $803,000 after buying an additional 1,051 shares during the period. Finally, HighTower Advisors LLC increased its stake in shares of Integer by 2.9% during the first quarter. HighTower Advisors LLC now owns 7,831 shares of the medical equipment provider's stock valued at $632,000 after buying an additional 217 shares during the period. 99.29% of the stock is currently owned by hedge funds and other institutional investors.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.